Follow on Google News
News By Tag
News By Place
Follow on Google News
Brown University and UCSF Researchers Win CureAccelerator Live! for Diversity, Equity & Inclusion
Clinical Repurposing Trials in Bladder Cancer and Seizures after Cardiac Arrest Receive Funding
As a leading global nonprofit focused on repurposing research as a fast track to impacting patients, Cures Within Reach's CureAccelerator Live! competition showcases clinical repurposing trials that are ready to fund. Held in partnership with DIA's Advancing Diversity, Equity, and Inclusion Across Life Sciences R&D Meeting, CureAccelerator Live! featured four researchers representing academic medical centers from across the US, and its attendees voted for the winning clinical repurposing trials impacting health disparities and/or led by an underserved racial/ethnic minority researcher.
"During a cardiac arrest, the heart stops beating normally and there is loss of blood flow to the brain. Damage to the brain can cause seizures, and nearly all patients with this complication die from it," said Dr. Amorim, Director of the Epilepsy Service at the Zuckerberg San Francisco General Hospital and Assistant Professor of Neurology at the University of California, San Francisco. "We are thrilled for Cures Within Reach's support of a clinical trial focused on preventing seizures and accelerating recovery of patients with cardiac arrest."
"Thank you to Cures Within Reach and its philanthropic funding partners, for the patient-facing impactful work that you do" said Dr. Holder. "We are extremely excited to receive funding to target androgen signaling in bladder cancer. We believe that this clinical trial may potentially lead to a change in standard of care therapy for bladder cancer."
"These clinical trials highlight the opportunity that testing approved therapies can have on patients with rare diseases and health disparities issues as well as the catalytic impact of funding underserved minority clinicians and researchers across the US," said Barbara Goodman, President & CEO at Cures Within Reach. "We are thrilled to support both Drs. Amorim and Holder and hope to raise funding for the other two finalists later this year."
The other finalists who presented their repurposing trials at CureAccelerator Live! included:
Expert panelists from Burroughs Wellcome Fund, Harding University, Horizon Therapeutics and University of Illinois at Chicago represented clinicians, research, industry and philanthropy and helped attendees make a more informed voting decision.
Cures Within Reach is grateful for philanthropic and industry support for its Diversity, Equity & Inclusion Community from Takeda Pharmaceuticals' Center for Health Equity and Patient Affairs, the Searle Funds at The Chicago Community Trust, Adtalem Global Education Foundation, Burroughs Wellcome Fund, Horizon Therapeutics, Walder Foundation, Westlake Health Foundation, individual donors and others.
About Cures Within Reach
Cures Within Reach (CWR) is a US-based philanthropic leader improving patient quality and length of life by leveraging the speed, safety and cost-effectiveness of medical repurposing research: driving more treatments to more patients more quickly. CWR catalyzes research to facilitate and validate already approved therapies for new indications to create clinical impact. CWR provides seed funds for first in-human or pivotal studies that, when successful, allow a catalytic effect of additional follow-on trials and follow-on funding. CWR's 2022 main initiatives include focused efforts to impact Diversity, Equity & Inclusion; Veterans; and Pediatrics. CWR currently has a global portfolio of 36 funded trials at 30 institutions in 26 diseases. Visit cureswithinreach.org (http://www.cureswithinreach.org/
Clare Thibodeaux, PhD